Drugs / Buloxibutid
Buloxibutid
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06157580 | Dec 2023 → Oct 2024 | preeclampsia | Anna Stanhewicz, PhD | Completed | No outcome recorded |
| Phase 0 | NCT05937841 | Jun 2023 → Aug 2025 overdue | preeclampsia | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT05576155 | Oct 2022 → Feb 2023 | — | Anna Stanhewicz, PhD | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05277922 | Apr → May 2022 | isoproterenol-mediated vasodilatation | Vicore Pharma AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06588686 | Dec 2024 → May 2027 expected | idiopathic pulmonary fibrosis | Vicore Pharma AB | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2026-08-24 | Vicore Pharma AB | Results Vicore Pharma to Present at the European Respiratory Society Congress 2026 vicorepharma.com ↗
Buloxibutid (C21) activates the angiotensin II type 2 receptor in alveolar epithelial type II cells, increasing MMP-13 associated with fibrosis resolution in idiopathic pulmonary fibrosis |
| 2026-04-29 | Vicore Pharma AB | Results Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference vicorepharma.com ↗
Buloxibutid Stabilizes and Improves Lung Function in Idiopathic Pulmonary Fibrosis and Elevates Plasma MMP-13, Linking AT2 Receptor Activation in Alveolar Epithelial Type 2 Cells to Resolution of Fibrosis |
| 2025-09-30 | Vicore Pharma AB | Regulatory Buloxibutid Receives Orphan Drug Designation in Japan for the Treatment of Idiopathic Pulmonary Fibrosis vicorepharma.com ↗
Stockholm, September 30, 2025 – Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Drug designation to buloxibutid for the treatment of idiopathic pulmonary fibrosis (IPF). |
| 2025-09-23 | Vicore Pharma AB | Results Vicore Announces Presentations at the European Respiratory Society Congress 2025 vicorepharma.com ↗
Among patients with comparable baseline characteristics, buloxibutid showed statistically significant improvement in forced vital capacity (FVC) at 36 weeks relative to both baseline and synthetic control, confirming the disease-modifying signal observed in the AIR trial. |
| 2025-05-22 | Vicore Pharma AB | Results Vicore Presents New Data at the 2025 American Thoracic Society International Conference vicorepharma.com ↗
A key finding in the Phase 2a AIR trial was that a substantial proportion of participants demonstrated improvement in lung function. |
| 2025-01-29 | Vicore Pharma AB | Regulatory The FDA Grants Vicore’s Buloxibutid Fast Track Designation for Idiopathic Pulmonary Fibrosis vicorepharma.com ↗
the United States Food and Drug Administration (FDA) has granted Fast Track designation to its lead candidate buloxibutid |
| 2024-05-20 | Vicore Pharma AB | Results Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis vicorepharma.com ↗
Vicore Pharma Holding AB (STO: VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), announced positive final results from its Phase 2a AIR trial evaluating buloxibutid (C21) in idiopathic pulmonary fibrosis (IPF). |
| 2018-03-21 | Vicore Pharma AB | Results Frontiers in Physiology publish data with C21 on pulmonary fibrosis vicorepharma.com ↗
In both cases, treatment with C21 almost completely prevented the further development of fibrosis. |
| 2018-01-26 | Vicore Pharma AB | Results Highlights from new publications on C21 and the AT2 receptor vicorepharma.com ↗
Two recent published articles summarize inhibited fibrotic activity in Dupuytren disease and beneficial effect of AT2 receptor stimulation on glucose/insulin metabolism. |
| 2017-05-03 | Vicore Pharma AB | Results New positive study results on diabetic nephropathy with Vicore Pharma’s candidate drug C21 vicorepharma.com ↗
The results from the recent study show that the combination of C21 and an ARB can offer further kidney protection to this vulnerable group of patients |
All press releases naming this drug 13 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Buloxibutid | “Buloxibutid (also known as C21) is a potent and selective angiotensin II type 2 receptor (AT2R) agonist, in development for oral treatment of fibrotic lung disease.” PMID 38344891 ↗ Feb 2024 |
| Known as | C21 | “Buloxibutid (also known as C21) is a potent and selective angiotensin II type 2 receptor (AT2R) agonist, in development for oral treatment of fibrotic lung disease.” PMID 38344891 ↗ Feb 2024 |
| Known as | Compound 21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05937841 ↗ |
| Known as | T2 agonist compound 21 | ChEMBL registry synonym — accepted as the source's own label CHEMBL189568 ↗ |
| Action | Activate | “Buloxibutid (also known as C21) is a potent and selective angiotensin II type 2 receptor (AT2R) agonist” PMID 38344891 ↗ Feb 2024 |
| Modality | Small molecule | — CHEMBL189568 ↗ |
| Route | Other | “through local intra-arterial infusions for 5 min/dose” NCT05277922 ↗ |